World Disease Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of World Disease Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Aspergillosis Therapy
Researchers from Kyushu University detail new studies and findings in the area of aspergillosis therapy
July 28th, 2009
A new study, 'Combination therapy with micafungin and amphotericin B for invasive pulmonary aspergillosis in an immunocompromised mouse model,' is now available. "Antifungal monotherapy with polyenes, azoles or echinocandins is not always effective for invasive pulmonary aspergillosis (IPA). The main purpose of this study was to evaluate the efficacy of a combination of micafungin and amphotericin B for the primary treatment of IPA in an immunocompromised mouse model," scientists writing in the Journal of Antimicrobial Chemotherapy report. "Female ICR mice were used in all experiments. An immunosuppressive state was induced in mice by an intraperitoneal injection...
Source: World Disease Weekly (2009-07-28)
|
